Company: INTS
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001567264-25-000077
Chunk: 18

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 18
---
Item 1. Condensed Financial Statements

INTENSITY THERAPEUTICS, INC.

CONDENSED BALANCE SHEETS

(in thousands, except share and per share amounts)

June 30,2025December 31,2024(Unaudited)*ASSETSCurrent assets:Cash and cash equivalents$2,216 $2,590 Prepaid expenses and other current assets822 773 Total current assets3,038 3,363 Right-of-use asset, net109 122 Other assets1,296 1,298 Total assets$4,443 $4,783 LIABILITIES AND STOCKHOLDERS’ EQUITYCurrent liabilities:Accounts payable$1,193 $1,219 Accrued expenses941 508 Lease liability, current portion30 28 Total current liabilities2,164 1,755 Lease liability, long-term portion95 110 Total liabilities2,259 1,865 Commitments and contingenciesStockholders' equity:Preferred stock, par value $.0001. Authorized shares of 15,000,000 as of both June 30, 2025 and December 31, 2024. None issued and outstanding as of both June 30, 2025 and December 31, 2024.— — Common stock, par value $.0001. Authorized shares of 135,000,000 as of June 30, 2025 and December 31, 2024, respectively. Issued and outstanding shares of 26,166,423 and 15,122,873 as of June 30, 2025 and December 31, 2024, respectively.3 2 Additional paid-in capital74,848 69,699 Accumulated deficit(72,667)(66,783)Total stockholders’ equity2,184 2,918 Total liabilities and stockholders’ equity$4,443 $4,783 

*Derived from audited financial statements

The accompanying notes are an integral part of these condensed financial statements.

1

Table of Contents

INTENSITY THERAPEUTICS, INC.

CONDENSED STATEMENTS OF OPERATIONS

(in thousands, except share and per share amounts)

(Unaudited)

Three Months Ended June 30,Six Months Ended June 30,2025202420252024Operating expenses:Research and development$1,541 $3,563 $3